Introduction
Heart failure (HF) is a clinical syndrome characterized by typical symptoms and signs resulting from an abnormality of cardiac structure and/or function. 1 Traditionally, two forms of HF defined by left ventricular ejection fraction (LVEF), i.e. HF with reduced LVEF (<40%; HFrEF) and preserved LVEF (≥50%; HFpEF), have been acknowledged. 1, 2 Although still a matter of debate, a number of arguments, such as the bimodal distribution of LVEF in epidemiological HF studies and registries, differences in the patient populations and the specific pattern of left ventricular remodelling support the view that HFpEF is a distinct disease entity rather than simply a transitory stage from normal to HFrEF. 3 In support of this line of evidence, therapies that have been shown to improve outcomes in patients with HFrEF (i.e. LVEF < 35-40%) revealed disappointing results in large HFpEF outcome trials. 4 -6 Mean LVEF in the latter studies ranged between 54 and 60%. While the populations with HFrEF and HFpEF have been extensively studied, it is not known whether patients with HF and a LVEF in the 'grey zone' of 40-49% share characteristics with HFrEF or HFpEF, or have to be regarded as a separate additional phenotype. 7 The current American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines 2 state that 'characteristics, treatment patterns and outcomes in this population (LVEF 41-49%; HFpEF borderline) appear similar to those of patients with HFpEF'. The recent European Society of Cardiology (ESC) guidelines 1 introduced the new category of HF with mid-range LVEF (HFmrEF) defined as LVEF of 40-49% in order to stimulate research into the underlying characteristics, pathophysiology, and treatment of this group of patients characterized as having 'most probably primarily mild systolic dysfunction but with features of diastolic dysfunction '. Therefore, using the detailed database from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF), 8 it was the purpose of the present analysis to compare clinical characteristics, comorbidities, quality of life, laboratory findings, Doppler echocardiography, prognosis, and response to more intensified therapy [i.e. N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided] in patients with HFrEF (LVEF < 40%), HFmrEF (LVEF 40-49%), and HFpEF (LVEF ≥ 50%) in this population with established HF including the whole spectrum of LVEF.
Methods

TIME-CHF study
The detailed design of the TIME-CHF study programme 8 and the principal findings were reported previously. 9, 10 In short, TIME-CHF was a prospective randomized controlled multicentre trial addressing the management of elderly patients with HF comparing a standard symptom-guided therapy with an intensified, NT-proBNP-guided medical therapy. The study included 622 patients aged ≥60 years, with symptomatic HF (NYHA class ≥ II), a history of HF hospitalization within the preceding year, and a NT-proBNP level higher than twice the upper limit of normal. Some exclusion criteria applied, but on average, the patients did not differ much from those included in large registries. Guideline-recommended medication was intensified
according to predefined escalation rules with the goal to reduce symptoms to NYHA class II or less in the symptom-guided group and to additionally reduce NT-proBNP levels to less than two times the upper limit of normal (i.e. 400 ng/L in those aged 60-74 years and 800 ng/L in those ≥75 years) in the NT-proBNP-guided group. Patients were followed clinically with pre-specified visits after 1, 3, 6, 12, and 18 months. After the predefined 18-month study period, 367 of 406 patients (90%) alive and participating in the study agreed to long-term follow-up, which was conducted by telephone contact and chart review, and was continued up to >5 years. Endpoints were survival free of all-cause hospitalizations, survival free of HF hospitalizations, overall survival (excluding cancer-related death by protocol), and quality of life.
The study complied with the Declaration of Helsinki, the research protocol was approved by the local Ethics Committees, and written informed consent was obtained for all patients prior to inclusion into the study.
Echocardiography
At study entry, the patients underwent a transthoracic echocardiography performed at the recruiting centre using standard clinical ultrasound equipment. The echocardiographic studies were stored digitally and transferred to the echocardiography core laboratory at the University Hospital of Basel, where the studies were read by two trained cardiologists blinded for all patient information. All measurements were done according to recommendations of the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI). 11 Left ventricular dimensions and the left atrial anteroposterior diameter were measured on a parasternal long axis view. M-mode imaging was used to derive medial and lateral mitral annular motions as well as tricuspid annular motion. Pulsed wave Doppler was used to derive mitral E and A wave velocities, mitral deceleration time and isovolumic relaxation time as well as septal annular tissue velocity. The systolic pressure gradient across the tricuspid valve was measured using continuous wave Doppler. Apical four chamber and apical two chamber views were used to derive LVEF, left ventricular end-diastolic volume index and left ventricular end-systolic volume index using the biplane Simpson's method. Left atrial area was measured in the apical four chamber view. Overall, the correlation between LVEF at the recruiting centres and at the core-lab was good, independent of image quality (R 2 = 0.62). 12 For the present analysis, patients were stratified in three groups (HFrEF, LVEF < 40%; HFmrEF, LVEF 40-49%; and HFpEF, LVEF ≥ 50%) according to the LVEF measured at the centres, which was available in all patients and was used for inclusion of patients into the study.
All calculations were performed using the SPSS statistical package version 23 .0 (SPSS Inc., Chicago, IL, USA).
Results
Prevalence of heart failure with mid-range ejection fraction
In this population of 622 patients with established HF including the whole range of LVEFs, 402 (65%) were classified as having HFrEF, 108 (17%) as HFmrEF, and 112 (18%) as HFpEF.
Clinical characteristics
As shown in Table 1 
Comorbidities
The groups shared in general a comparable and high burden of comorbidities with an identical Charlson score as depicted in Table 2 . Manifestations of atherosclerosis were most prevalent in HFmrEF with a statistically significant difference to HFpEF. On the other hand, anaemia was found more and liver disease less frequently in HFmrEF as compared with HFrEF.
Quality of life
Impaired quality of life was documented in the study population without significant differences among groups ( Table 3) .
Echocardiography
Left ventricular cavity dimensions gradually increased from HFpEF to HFmrEF to HFrEF ( 
Laboratory results
NT-proBNP levels were elevated to a similar extent in HFrEF and HFmrEF, and significantly higher in both these groups than in HFpEF. HFmrEF patients also leaned more towards HFrEF patients with respect to higher serum creatinine and troponin T as compared with HFpEF. On the other hand, HFmrEF patients resembled HFpEF more with regard to higher cystatin C and total procollagen type 1 amino-terminal propeptide (tP1NP) levels and lower SGPT, prealbumin, and haemoglobin than in patients with HFrEF ( Table 5) .
Prognosis
During a median follow-up of 794 days (IQR 422-1226), 247/622 patients (39.7%) died. Of those, six died of cancer and were censored at the time of death. A total of 480 patients (77%) experienced the endpoint of all-cause hospitalization or death and 317 patients (51%) the disease-specific endpoint of HF hospitalization or death. Survival free of all-cause hospitalizations (25, 19, 21%; P = 0.08), survival free of HF hospitalizations (51, 44, 48%; P = 0.29) and overall survival (62, 58, 61%; P = 0.92) were not significantly different between the groups with HFrEF, HFmrEF, and HFpEF, respectively ( Figure 1) . No significant effect of NT-proBNP-guided therapy resulted with respect to survival free of all-cause hospitalizations and overall survival in the three populations ( Figure 2) . In contrast, different effects of NT-proBNP-guided therapy were seen regarding survival free of HF hospitalizations with a demonstrable benefit in HFrEF (55 vs. 47%, P = 0.056) and HFmrEF (56 vs. 33%, P = 0.03), but not in HFpEF (44 vs. 52%, P = 0.28) as depicted in Figure 2 .
Discussion
We present several novel findings with respect to HFmrEF in a real-world population with established HF covering the whole spectrum of LVEF. A substantial proportion of patients with HF have a moderately reduced LVEF outside the commonly used cut-offs for HFrEF and HFpEF. Although this population shares some characteristics with HFpEF or HFrEF, it is in many aspects intermediate between HFrEF and HFpEF. Coronary artery disease was the principal primary cause of HFrEF and HFmrEF, hypertensive heart disease in HFpEF. Clinical presentation and burden of comorbidities were otherwise similar, quality of life was comparably impaired and prognosis was equally poor in the three groups in our study. In terms of left ventricular remodelling, HFmrEF represents an intermediate stage between HFpEF and HFrEF. Interestingly, a significant benefit of NT-proBNP-guided therapy on the disease-specific endpoint of survival free of HF hospitalization was seen in the groups with HFrEF and HFmrEF, but not HFpEF, suggesting that HFmrEF ought to be categorized and treated as HFrEF.
Prevalence
Few data are available regarding the prevalence of patients with HFmrEF. In our study, 17% of patients were characterized as having HFmrEF, which is in accordance with previously reported prevalences of 14-18% 13 -18 despite the fact that study designs, settings, and LVEF cut-offs were different. 
Echocardiography
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61 (9) 52 (7) 48 (7 a similar prevalence of coronary artery disease independent of LVEF but did not state the causes of HF. In the study by Nadruz et al. 20 the prevalence of ischaemic cardiomyopathy was surprisingly low in all groups, likely explained by selection bias as a consequence of the study design. Traditionally, coronary artery disease has been regarded as having an adverse impact on prognosis in HFrEF, although it has not emerged as an important risk factor for outcome in risk prediction models. 21 It has been shown recently that HFpEF patients with coronary artery disease have a greater deterioration of LVEF and increased mortality during follow-up. 22 In the Epidémiologie et Thérapeutique de l'Insuffisance Cardiaque dans la Somme (ETICS) registry, 23 24 did not differ systematically among groups. While overall there is little data available looking specifically at the same LVEF groups as in our study, the values that we report correspond to recent data in subjects with HFpEF and HFrEF. 25 
Prognosis
Prognosis of HF is poor in general, but whether patients with HFpEF fare better than those with HFrEF or have a similar outcome is still a matter of debate. Only few data are available describing outcome in HFmrEF. In the present analysis, we found that all-cause hospitalization-free survival, overall survival, and HF hospitalization-free survival in HFmrEF was similar to HFrEF and HFpEF without significant differences in outcomes in this 'real-world' population. This is in accordance with the results of the Cardiovascular Health Study 13 and the study by Nadruz et al. 20 In community-based studies of asymptomatic left ventricular systolic dysfunction participants with borderline LVEF of 40-50% were found to have a poorer prognosis compared with those with LVEF > 50%. 7 Similarly, the incidence of both the composite of cardiovascular death, aborted cardiac arrest, or hospitalization for HF and of cardiovascular death was substantially higher in subjects with lower LVEF (44-50 vs. >50%) in TOPCAT. 26 Registries of acute HF reported an inverse correlation of in-hospital mortality with LVEF, whereas short-term mortality after discharge was comparable irrespective of LVEF. 15, 19 On the other hand, a graded relationship between lower LVEF and higher risk of events has been demonstrated in patients with stable chronic HF only with LVEFs Figure 2 All-cause hospitalization-free survival (left), survival (centre), and heart failure (HF) hospitalization-free survival (right) in patients with HF with reduced ejection fraction (top), HF with mid-range ejection fraction (middle), and HF with preserved ejection fraction (bottom) according to treatment strategy: symptom-guided strategy (red); NT-proBNP-guided strategy (green).
< 40-45% but with relatively stable event rates with higher LVEFs in CHARM 14 and MAGGIC 27 , suggesting that HFmrEF resembles HFpEF more than HFrEF in terms of outcome. These conflicting results are likely explained by different patient populations and study designs. No study to date has specifically evaluated the effect of pharmacological HF treatment in HFmrEF. Our results showing a demonstrable benefit of NT-proBNP-guided therapy regarding survival free of HF hospitalizations in HFrEF and HFmrEF, but not in HFpEF, are therefore of interest, even though not pre-specified. CHARM-Preserved 4 enrolled patients with a higher prevalence of coronary artery disease and the lowest LVEF (≥40%) compared with other HFpEF trials with ACE-inhibitors or angiotensin-receptor blockers and showed a benefit regarding hospital admissions for HF in the candesartan group compared with placebo. In addition, in a subgroup analysis of TOPCAT, 26 the potential efficacy of spironolactone was only seen at the lower end of the LVEF spectrum studied. 
Limitations
A number of limitations apply to this study. First, we performed a post hoc analysis of the TIME-CHF study and the HFmrEF group was not pre-defined. In addition, TIME-CHF was a mid-size clinical trial and the number of patients with mid-range LVEF was relatively low to draw final conclusions. However, given the paucity of publications on this subject, we provide some novel hypothesis-generating data which, in our opinion, merit further investigation and may be of clinical importance. Second, TIME-CHF included only patients >60 years of age. Our results may, therefore, not be representative for younger subjects with HF. Third, since recruitment in TIME-CHF was based on certain NT-proBNP cut-offs, a selection bias might be present, as patients with less severe HF were not included. Fourth, LVEF was determined at baseline; it is conceivable that LVEF improved or deteriorated in some patients before or during the course of the study. However, time since diagnosis did not differ between the three groups, making it unlikely that potential misclassification of patients significantly influenced the results (data not shown). In addition, echocardiography was not available for the core lab in all patients as previously reported, and variability of LVEF may be relevant.
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However, echocardiography performed as part of the clinical routine is still the standard for determining cardiac structure and function, making our results clinically relevant. Also, biomarkers were not measured in all patients. Finally, it could be argued that the LVEF cut-offs defined for this study are arbitrary. However, the cut-offs were chosen as advocated by current guidelines.
1,2
Conclusions
Many of the results of the present analysis show HFmrEF to be intermediate between HFrEF and HFpEF, but the primary cause of HF and the response to therapy was similar in HFmrEF and HFrEF. Clearly, more studies are needed to further characterize this population with HFmrEF and to investigate whether these patients, contrary to HFpEF, equally benefit from established treatment for HFrEF. In this case, a LVEF partition value of 50% would be appropriate to distinguish HFrEF and HFpEF.
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